<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841854</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0088</org_study_id>
    <nct_id>NCT00841854</nct_id>
  </id_info>
  <brief_title>Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication</brief_title>
  <official_title>Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pacific Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, triple therapy are recommended by various guidelines for the treatment of
      Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment
      failure rates with one week first line clarithromycin based triple therapy necessitating
      salvage strategy to eradicate H. pylori in primary treatment failure. However, the exact
      duration of bismuth based second line treatment is not determined. Therefore, the
      investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple
      regimen as a second-line therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whether the two week group yield a higher eradication rate comparing to the one week group.</measure>
    <time_frame>At least four week after completion of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effect</measure>
    <time_frame>four weeks after completion of medication</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">199</enrollment>
  <condition>Helicobacter Infection</condition>
  <arm_group>
    <arm_group_label>PBMT7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBMT14</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole</intervention_name>
    <description>pantoprazole 40mg bid</description>
    <arm_group_label>PBMT7</arm_group_label>
    <arm_group_label>PBMT14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bismuth</intervention_name>
    <description>bismuth 300mg qid</description>
    <arm_group_label>PBMT7</arm_group_label>
    <arm_group_label>PBMT14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole</intervention_name>
    <description>metronidazole 500mg tid</description>
    <arm_group_label>PBMT7</arm_group_label>
    <arm_group_label>PBMT14</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracycline</intervention_name>
    <description>tetracycline 500mg qid</description>
    <arm_group_label>PBMT7</arm_group_label>
    <arm_group_label>PBMT14</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  H. pylori infection

          -  Aged between 18-80 years

          -  Are willing to received eradication therapy for H. pylori

        Exclusion Criteria:

          -  Children and teenagers aged less than 18 years or over 80 years

          -  Previous eradication therapy for H. pylori

          -  History of gastrectomy

          -  Previous allergic reaction to antibiotics

          -  Use of prompt pump inhibitors and antibiotics in the recent 4 weeks

          -  Active upper GI bleeding in the recent 1 week

          -  Contraindication to treatment drugs

          -  Pregnant or lactating women

          -  Severe concurrent disease or malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hwoon-Yong Jung, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Hwoon-Yong Jung</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Bismuth</keyword>
  <keyword>Salvage treatment</keyword>
  <keyword>Metronidazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

